<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9932">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05687253</url>
  </required_header>
  <id_info>
    <org_study_id>BDX-22-006</org_study_id>
    <nct_id>NCT05687253</nct_id>
  </id_info>
  <brief_title>Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Active-Controlled, Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baudax Bio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baudax Bio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of Intubation conditions following administration of neuromuscular blocking&#xD;
      agents; BX1000 (investigational) or rocuronium (active control).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intubation conditions will be assessed in anesthetized subjects undergoing an elective&#xD;
      surgical procedure utilizing general anesthesia. Following administration of IV anesthesia,&#xD;
      subjects will have electromyography (EMG) neuromuscular monitoring device applied prior to&#xD;
      administration of neuromuscular blocking agent (NMBA). NMBA will be administered and&#xD;
      assessment of intubation conditions will begin 60 seconds after administration according to&#xD;
      the methods defined in Viby-Mogensen 1996; assessment will be repeated at 90 and 120 seconds&#xD;
      after administration when intubation has not already been completed.&#xD;
&#xD;
      After intubation is completed, subjects will progress to have their elective surgery&#xD;
      completed and will be maintained under general anesthesia until neuromuscular function is&#xD;
      recovered. Once recovered from anesthesia and extubation, subjects will be monitored in a&#xD;
      recovery area until they are suitable to be discharged to the inpatient floor, after which&#xD;
      time they may be discharged at the clinical discretion of the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, active controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Intubation Conditions</measure>
    <time_frame>Within 2 minutes after administration</time_frame>
    <description>Assessment of Intubation Conditions (Poor, Good, Excellent) Following Administration of Neuromuscular Blocking agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Safety And Tolerability - Adverse Events</measure>
    <time_frame>Within 30 days after administration</time_frame>
    <description>Assessment of Incidence of Adverse Events Following Administration of Neuromuscular Blocking agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Safety And Tolerability - Blood Pressure</measure>
    <time_frame>Within 30 days after administration</time_frame>
    <description>Assessment of Changes in Blood Pressure Following Administration of Neuromuscular Blocking agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Safety And Tolerability - Heart Rate</measure>
    <time_frame>Within 30 days after administration</time_frame>
    <description>Assessment of Changes in Heart Rate Following Administration of Neuromuscular Blocking agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Safety And Tolerability - Blood Oxygen Saturation</measure>
    <time_frame>Within 30 days after administration</time_frame>
    <description>Assessment of Changes in Vital signs Following Administration of Neuromuscular Blocking agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Onset of Neuromuscular Blockade</measure>
    <time_frame>Within 1 day after administration</time_frame>
    <description>Measurement of Twitch Suppression via Electromyography Following Administration of Neuromuscular Blocking agent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Neuromuscular Recovery</measure>
    <time_frame>Within 1 day after administration</time_frame>
    <description>Measurement of Twitch Recovery via Electromyography Following Administration of Neuromuscular Blocking agent</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <condition>Anesthesia</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>BX1000 0.15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BX1000 0.15 mg/kg IV Bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BX1000 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BX1000 0.25 mg/kg IV Bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BX1000 0.35 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BX1000 0.35 mg/kg IV Bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium 0.6 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium bromide 0.6 mg/kg IV Bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BX1000</intervention_name>
    <description>IV BX1000</description>
    <arm_group_label>BX1000 0.15 mg/kg</arm_group_label>
    <arm_group_label>BX1000 0.25 mg/kg</arm_group_label>
    <arm_group_label>BX1000 0.35 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium Bromide</intervention_name>
    <description>IV Rocuronium</description>
    <arm_group_label>Rocuronium 0.6 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Providing informed consent&#xD;
&#xD;
          -  Undergoing elective surgery utilizing IV general anesthesia&#xD;
&#xD;
          -  Normal airway assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable disease or emergency surgical conditions&#xD;
&#xD;
          -  Known hypersensitivity to rocuronium, other NMB or study medications&#xD;
&#xD;
          -  History of anaphylaxis&#xD;
&#xD;
          -  History of neuromuscular junction disease&#xD;
&#xD;
          -  Personal or family history of malignant hyperthermia or pseudocholinesterase&#xD;
             deficiency&#xD;
&#xD;
          -  Diagnosed or suspected sleep apnea&#xD;
&#xD;
          -  History of prior anesthetic complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Baudax Medical Monitor</last_name>
    <phone>484-395-2440</phone>
    <email>info@baudaxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Researcher MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 9, 2022</study_first_submitted>
  <study_first_submitted_qc>January 6, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 6, 2023</last_update_submitted>
  <last_update_submitted_qc>January 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intubation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

